EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer

Fabiana Napolitano, Yunguan Wang, Dhivya R Sudhan, Paula I Gonzalez-Ericsson, Luigi Formisano, Nisha Unni, Shahbano Shakeel, James Z Zhu, Khushi Ahuja, Lei Guo, María Rosario Chica-Parrado, Yuki Matsunaga und 19 weitere

Journal of Clinical Investigation · 02.02.2026 · 136 (3)

DOI: 10.1172/jci188458 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 09.12.2025. Verfasst von Fabiana Napolitano und 30 weiteren Autor:innen. Beteiligte Einrichtung: UT Southwestern Simmons Comprehensive Cancer Center, Department of Internal Medicine, University of Texas Southwestern (UTSW) Medical Center, Dallas,…. Hauptthemen laut MEDLINE: Breast Neoplasms, Tumor Microenvironment, CD8-Positive T-Lymphocytes, Lymphocytes, Tumor-Infiltrating. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of the tumor immune microenvironment (TIME) in modulating responses to antiestrogen therapy in hormone receptor–positive (HR + ) breast cancers remains unclear. We analyzed pre- and on-treatment biopsies from patients with HR + breast cancer treated with letrozole to induce estrogen deprivation (ED). Stromal tumor–infiltrating lymphocytes, assessed by H&E staining, and immune-related gene sets, including IFN-γ signaling genes, measured by RNA-Seq, were increased in ED-resistant tumors. Cyclic immunofluorescence and spatial transcriptomics revealed an abundance of CD8 + T cells and enhanced antigen processing and immune gene signatures in ED-resistant tumors. In this group, the expression of CXCL9 , CXCL10 , and CXCL11 — chemokine genes involved in CD8 + T cell recruitment — and the CXCR3 receptor were upregulated both before and after letrozole treatment. CXCL11 levels were higher in conditioned media from HR + breast cancer cells cocultured with CD8 + T cells. Both recombinant CXCL11 and coculture with CD8 + T cells promoted MCF7 and T47D cell growth in estrogen-free conditions. Finally, deletion combined with silencing of the CXCL11 receptors CXCR3 and CXCR7 in MCF7 cells impaired proliferation in response to exogenous CXCL11 and to coculture with CD8 + T cells in estrogen-free conditions. These findings suggest that CD8 + T cell–associated CXCL11 in the TIME modulated the response of HR + breast cancer cells to estrogen suppression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTumor MicroenvironmentCD8-Positive T-LymphocytesLymphocytes, Tumor-InfiltratingNeoplasm ProteinsAntineoplastic Agents, HormonalHumansFemaleLetrozoleReceptors, CXCR3MCF-7 CellsChemokine CXCL11Cell Line, Tumor

Stichwörter der Autor:innen

Breast cancerChemokinesDrug therapyImmunologyOncology

Substanzen

LetrozoleReceptors, CXCR3CXCL11 protein, humanChemokine CXCL11CXCR3 protein, humanNeoplasm ProteinsAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • UT Southwestern Simmons Comprehensive Cancer Center, Department of Internal Medicine, University of Texas Southwestern (UTSW) Medical Center, Dallas, Texas, USA.
  • Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Division of Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.
  • Departments of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center (VUMC), Nashville, Tennessee, USA.
  • Department of Medical Oncology.

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • National Cancer Institute
  • U.S. Department of Defense
  • Cancer Prevention and Research Institute of Texas
  • Susan G. Komen Breast Cancer Foundation
  • Breast Cancer Research Foundation

Zitieren

APA

Napolitano, F., Wang, Y., Sudhan, D. R., Gonzalez-Ericsson, P. I., Formisano, L., Unni, N., Shakeel, S., Zhu, J. Z., Ahuja, K., Guo, L., Chica-Parrado, M. R., Matsunaga, Y., Luna, P., Lin, C. A., Uemoto, Y., Lee, K. M., Ma, H., Evans, N. J., Servetto, A., …, & Arteaga, C. L. (2026). CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer. Journal of Clinical Investigation, 136(3). https://doi.org/10.1172/jci188458

Vancouver

Napolitano F, Wang Y, Sudhan DR, Gonzalez-Ericsson PI, Formisano L, Unni N, et al. CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer. Journal of Clinical Investigation. 2026;136(3). doi:10.1172/jci188458

BibTeX
@article{Napolitano2026,
  author = {Napolitano, Fabiana and Wang, Yunguan and Sudhan, Dhivya R and Gonzalez-Ericsson, Paula I and Formisano, Luigi and Unni, Nisha and Shakeel, Shahbano and Zhu, James Z and Ahuja, Khushi and Guo, Lei and Chica-Parrado, María Rosario and Matsunaga, Yuki and Luna, Pamela and Lin, Chang-Ching A and Uemoto, Yasuaki and Lee, Kyung-Min and Ma, Hongli and Evans, Nathaniel J and Servetto, Alberto and Mendiratta, Saurabh and Barnes, Spencer D and Bianco, Roberto and Fang, Yisheng V and Xu, Lin and Lee, Jeon and Wang, Tao and Balko, Justin M and Mills, Gordon B and Labrie, Marilyne and Hanker, Ariella B and Arteaga, Carlos L},
  title = {CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {3},
  doi = {10.1172/jci188458}
}
Kostenlos starten →